A major obstacle for developing effective immunotherapy, including CAR-T therapy for GBM, is the extremely complex tumor microenvironment that compromises immune response by secretion of immunosuppressive cytokines including TGFβ (9, 28–30). The gene discussed is TGFB1; the disease is glioblastoma.